Pulmonary arterial hypertension, or PAH, is a rare and severe disease characterized by elevated blood pressure in the ...

Add Yahoo as a preferred source to see more of our stories on Google. Oct. 31—(StatePoint) November is Pulmonary Hypertension Awareness Month, and the American Lung Association, with support from ...

NOTCH3-ECD is a specific IPAH biomarker, Cloud-Clone’s SEL147Hu ELISA Kit powers this breakthrough HUSTON, TX, UNITED STATES, March 17, 2026 /EINPresswire.com/ — A groundbreaking study published in ...

Credit: Merck. Winrevair is a first-in-class recombinant activin receptor type IIA-Fc fusion protein designed to bind to activin A and other TGF-β superfamily ligands. The Food and Drug Administration ...

Lindsay talks about the difficult road of managing a pulmonary arterial hypertension diagnosis, and how a newly discovered medication helped secure her future.

Panelists discuss how riociguat targets the nitric oxide pathway and is approved for both Group 1 PAH and Group 4 chronic thromboembolic pulmonary hypertension, with specific patient selection ...

This transcript has been edited for clarity. Vallerie McLaughlin, MD: Hello and welcome to this Medscape InDiscussion on pulmonary arterial hypertension (PAH). Our topic today is the very important ...

Panelists discuss how managing patients with comorbidities requires careful evaluation to distinguish true Group 1 PAH features from underlying cardiac or pulmonary disease, with a more measured ...

GSK PLC (LSE:GSK, NYSE:GSK) has agreed to acquire Canadian biotech 35Pharma for $950 million in cash, securing a ...

The prevalence of SSc among Alaska Native and American Indian adults is comparable to or higher than other populations, with high GI and pulmonary involvement.

Pulmonary hypertension is traditionally defined as a mean pulmonary artery pressure of ≥25 mmHg when a patient is at rest, though a mean pressure of >20 mm Hg is considered to be abnormal and may ...